BioAffinity Technologies (BIAF) announced it has received a notification of allowance from the United States Patent and Trademark Office for a new patent covering the AI-built algorithm and flow cytometry platform that analyzes cell populations in sputum leading to detection of lung cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Regains Nasdaq Compliance, Ensures Continued Trading
- BioAffinity Technologies regains compliance with Nasdaq
- bioAffinity Technologies Announces $1.8M Direct Offering
- BioAffinity Technologies announces closing of $1.8M registered direct offering
- BioAffinity Technologies announces $1.8M registered direct offering